Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome

详细信息    查看全文

• 作者：Silmara Montalv&atilde ; o^a ; ^{silmara@unicamp.br} ; Priscila Soares Elí ; dio^a ; ^{pri_kelidio@hotmail.com} ; Sabrina da Silva Saraiva^a ; ^{sabrina_saraiva@yahoo.com.br} ; Bruna de Moraes Mazetto^a ; ^{brunamazetto_1@hotmail.com} ; Marina Pereira Colella^a ; ^{marinasp@unicamp.br} ; Erich Viní ; cius de Paula^a ; ^b ; ^{erich@unicamp.br} ; Simone Appenzeller^c ; ^{appenzellersimone@gmail.com} ; Joyce Annichino-Bizzacchi^a ; ^b ; ^{joyce@unicamp.br} ; Fernanda Andrade Orsi ; MD ; PhD^a ; ^d ; ^{ferorsi@unicamp.br}
• 关键词：Antiphospholipid ; Antibodies ; Prognosis ; Domain 1
• 刊名：Thrombosis Research
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：148
• 期：Complete
• 页码：32-37
• 全文大小：358 K
• 卷排序：148

文摘

We evaluated the clinical relevance of testing for aβ2GP1-Dm1 in thrombotic APS. 40% of patients with positive aβ2GP1 presented aβ2GP1-Dm1 antibodies. Anti-β2GP1-Dm1 was not associated with the site of thrombosis or recurrence. Positive aβ2GP1-Dm1 was more prevalent in SLE and triple aPL positivity patients. Anti-β2GP1-Dm1 detected patients at risk for systemic autoimmunity.